NASDAQ:NVGN

Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia

SYDNEY, Nov. 12, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ: NVGN) today announced that a patent application covering two of its key lead superbenzopyran (SBP) drug candidates has been accepted in Australia.  According to Novogen North Ameri...

2015-11-12 08:04 2039

Novogen Applies for Long-term Options Listing

SYDNEY, Sept. 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today announced that it will apply for the listing of the Long-Term Options on ASX and anticipates that this request will be granted within the next week. An Appendix 3B has been ...

2015-09-30 10:52 2469

Novogen Announces The Outcome Of A Comprehensive Science Review

SYDNEY, Aug. 31, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed its comprehensive scientific review has identified high value opportunities for its ground-breaking technology platforms in areas of unmet patient ne...

2015-08-31 07:00 1901

Newly Appointed Acting CEO Outlines Immediate Plans for Novogen

SYDNEY, July 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed it is committed to progressing its ground-breaking technology platforms to Phase 1 clinical trials as soon as practicable and to ensure the Company delivers the bes...

2015-07-30 08:08 2116

Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board

SYDNEY, July 22, 2015 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board ofIain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limit...

2015-07-22 10:34 2273

Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma

SYDNEY, July 16, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblasto...

2015-07-16 15:37 2390

Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer

NEW YORK, July 14, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effective...

2015-07-14 07:00 2475

Novogen Announces the Chairman's Address at the Company's General Meeting

SYDNEY, June 24, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) announced today the Chairman's Address at the Company's General Meeting. Full text follows: Dear Shareholders, The Company is in a solid financial position. With $45M in cash, and t...

2015-06-24 10:54 2037

Anisina on Track to Enter Clinic in 2016

SYDNEY, June 24, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) (Company), announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it no...

2015-06-24 08:00 1751

Novogen to Present at Bio International Convention Philadelphia 2015

SYDNEY, June 12, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced today that Novogen Group CEO,Graham Kelly, will be presenting at the Bio International Convention 2015 ( BIO) being held at the Pennsylvania Convention Centre, 1101 Ar...

2015-06-12 12:15 1830

Studies Confirm TRXE-009 Crosses the Blood-brain Barrier

NEW YORK, June 5, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) confirms that a lipid formulation of TRXE-009 dosed intravenously to animals was able to deliver therapeutic concentrations of TRXE-009 to brain tissue. This confirms that the d...

2015-06-05 07:30 2130

Novogen Expands Board with Two New Appointments

SYDNEY, June 3, 2015 /PRNewswire/ -- Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of two new non-executive directors to its Board. MrBryce Carmine and MrIan Phillips will extend the Board to 6 members, inclusive of 5...

2015-06-03 09:20 2013

Novogen Limited Announces Closing of Rights Issue Entitlement Offer and Notice of Shortfall

SYDNEY, June 2, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the non-renounceable pro-rata rights issue entitlement announced on21 April 2015 (Rights Issue) was completed successfully. The Rights Issue off...

2015-06-02 11:47 1860

ATM Technology Extended with New Patent Lodgement

NEW YORK, May 28, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the lodgement with the US Patent Office of a key patent covering a novel family of compounds within the Company's anti-tropomyosin (ATM) drug te...

2015-05-28 10:02 1995

Novogen to Present at Brain Tumor Biotech Summit 2015

NEW YORK, May 27, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that it will present at the Brain Tumor Biotech Summit 2015, being held inNew York on May 29, 2015. The venue is the Lennox Hill Hospital, East 76th...

2015-05-27 06:00 1853

Novogen to Present at the 2015 Marcum Microcap Conference

SYDNEY and NEW YORK, May 26, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that it will present at the2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City...

2015-05-26 08:28 1778

Novogen to Present at Hong Kong Investor Conference

SYDNEY, May 18, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that company CEO, DrGraham Kelly, will be a presenting company at Asia Biotech Invest 2015May 20-21. The Novogen presentation is at 10.00 am May 20 a...

2015-05-18 09:08 1653

Anisina Confirmed as Effective Anti-Cancer Agent in Animal Studies

SYDNEY, May 14, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen (NRT:ASX; NVGN: NASDAQ), today announced that it has confirmed that drug candidate, Anisina, is an effective monotherapy against human melanoma in an animal model. The Company announced recently that Anisina was a...

2015-05-14 09:39 1901

Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells

SYDNEY and SAN DIEGO, May 8, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to...

2015-05-08 06:54 2225

Novogen Completes the Private Placement of Equity

SYDNEY, April 29, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (Novogen or Company), announced today that it has completed the placement to US institutional investors of 51,750,000 ordinary shares, raising a total of$15,525,000 (before costs)...

2015-04-29 15:32 2096
123